Application of immune attacking protection component for inactivated ASFV (African swine fever virus) serving as complex vaccine

Abstract

The invention discloses an application of an immune attacking protection component for an inactivated ASFV (African swine fever virus) serving as a complex vaccine, and relates to an African swine fever gene engineering recombinant living vectored vaccine, subunit vaccine or nucleic acid vaccine immune attacking protection component, namely, an inactivated African swine fever virus or mixture of the inactivated African swine fever virus and adjuvants such as polysaccharides. The inactivated African swine fever virus or the mixture of the inactivated African swine fever virus and the adjuvantssuch as the polysaccharides can improve the immune attacking protection effect of an African swine fever gene engineering recombinant living vectored vaccine, a subunit vaccine or a nucleic acid vaccine, and can realize 100% protection. Besides, the invention further provides the complex vaccine jointly prepared from the immune attacking protection component and the gene engineering recombinant living vectored vaccine, the subunit vaccine or the nucleic acid vaccine.

Description

Technical field: [0001] The invention discloses the use of inactivated ASFV as an immune challenge protection component of a compound vaccine; it relates to an immune challenge protection component of African swine fever genetic engineering recombinant live vector vaccine, subunit vaccine or nucleic acid vaccine, that is, inactivated African swine fever Mixture of virus or inactivated African swine fever virus with adjuvants such as polysaccharides. Inactivated African swine fever virus or the mixture of inactivated African swine fever virus and polysaccharide and other adjuvants can improve the immune challenge protection effect of African swine fever genetically engineered recombinant live vector vaccine, subunit vaccine or nucleic acid vaccine, achieving 100% protection; at the same time, the invention also provides a compound vaccine prepared by combining the immune challenge protection component and the genetically engineered recombinant live vector vaccine or subunit vac...

AI Technical Summary

Problems solved by technology

[0003] The structure of ASFV is complex, and the mechanisms of virus infection and immunity are unclear. Although the research on ASF vaccines began in the late 1960s, there have been many reports in recent years. The types mainly include attenuated live vaccines, inactivated vaccines, genetically engineered recombinant live vaccines, etc. , but they have not been successfully applied in practice due to their respective defects

Among them, for the attenuated live vaccine, whether it is an artificial gene-deleted attenuated strain or a naturally isolated attenuated strain, although pigs can produce certain protection against the virus after immunization, there will be dose-dependent side effects, including depression, loss of appetite, and fever. , viremia, hypergammaglobulinemia, pneumonia, joint swelling, lameness, chronic lesions, and dead pigs, etc., and will cause further spread of the virus and the potential risk of virulence reversion (Manso Ribeiro J et al., 1963; Leitao , A et al., 2001)

Inactivated vaccines and genetically engineered recombinant live vector vaccines or subunit vaccines are relatively safe, but the immune challenge protection effect is not ideal. For example, ASF inactivated vaccines prepared by various traditional methods are combined with new and efficient adjuvants such as Polygen TM or Emulsigen ® It is used in conjunction with two immunizations. Although it is safe to use and can produce high levels of antibodies, all pigs will die after being challenged with ASFV street strains (Blome S et al., 2014); and new genetic engineering vaccines such as nucleic acid vaccines, Subunit vaccines and genetically engineered recombinant live vector vaccines are used with immune adjuvants such as BioMize 0226 or ZTS-01, similar to inactivated vaccines, although they have good safety, they can also induce a large number of antibodies, IFNγ and CTL responses ( Lokhandwala et al., 2016; Lokhandwala et al., 2017), but the effect of immune challenge protection is not ideal, does not produce immune challenge protection or only 20-60% protection rate (Lokhandwala et al., 2019)

In conclusion, although inactivated vaccines and recombinant gene engineering vector vaccines are very safe for pigs compared with attenuated live vaccines, they can also produce good humoral immune responses and cellular immune responses when used with adjuvants, but neither of them can produce very good immune responses. Good immune attack protection effect

Images